Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia.

International audienceTo improve the etiological diagnosis of neurodegenerative dementias like Alzheimer's disease (AD) or frontotemporal dementia (FTD), we evaluated the value of individual and combined measurements of the following relevant cerebrospinal fluid (CSF) biomarkers: Tau, 181p-Tau, Aβ38, Aβ40, Aβ42, sAβPPα, and sAβPPβ. This study conducted in two centers included patients with FTD (n = 34), AD (n = 52), as well as a control group of persons without dementia (CTRL, n = 42). Identical clinical criteria and pre-analytical conditions were used while CSF biomarkers were measured using commercial single and multiplex quantitative immunoassays. Thorough statistical analyses, including ROC curves, logistic regressions, and decision trees, were performed. We validated in AD the specific increase of p-Tau levels and the decrease of Aβ42 levels, two biological hallmarks of this disease. Tau concentrations were highest in AD and intermediate in FTD when compared to CTRL. The most interesting results were obtained by focusing on amyloid biomarkers as we found out in FTD a significant decrease of sAβPPβ, Aβ38, and Aβ40 levels. Aβ38 in particular was the most useful biomarker to differentiate FTD subjects from the CTRL population. Combining p-Tau and Aβ38 led us to correctly classifying FTD patients with sensitivity at 85% and specificity at 82%. Significant changes in amyloid biomarkers, particularly for Aβ38, are therefore seen in FTD. This could be quite useful for diagnosis purposes and it might provide additional evidence on the interrelationship between Tau and AβPP biology which understanding is essential to progress towards optimal therapeutic and diagnostic approaches of dementia

Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40 and 42 in human cerebrospinal fluid

International audienceCerebrospinal fluid (CSF) biomarkers are now widely used for diagnosis of Alzheimer disease (AD) in atypical clinical forms, for differential and early diagnosis, or for stratification of patients in clinical trials. Among these biomarkers, different forms of amyloid peptides (Aβ) produced by the cleavage of a transmembrane precursor protein called APP (amyloid precursor protein) have a major role. Aβ peptides exist in different length the most common ones having 40 (Aβ40), 42 (Aβ42), or 38 (Aβ38) amino acids in length. APP processing by gamma-secretase releases also an amino-terminal secreted fragment called sAβPP-beta while an alternative nonamyloidogenic cleavage of APP, through an alpha-secretase, liberates another fragment called sAβPP-alpha. To decipher the molecular and pathological mechanisms leading to the production and the detection of these entities is essential for the comprehension and the prevention of AD. In this report, we present the results of the Keywords: Biomarkers CSF Soluble amyloid precursor proteins Aβ fragment peptides Alzheimer disease Dementi

Suivi de patients atteints de maladie d'Alzheimer et traités par la galantamine pendant un an

LYON1-BU Santé (693882101) / SudocSudocFranceF

Expérience du suivi en consultation-mémoire de patients atteints de la maladie d'Alzheimer et traités par anticholinestérasiques

LYON1-BU Santé (693882101) / SudocSudocFranceF

Utilisation du test des 5 mots pour comparer la mémoire épisodique de patients ayant une maladie d'Alzheimer et de patients ayant une démence fronto-temporale à variante comportementale

LYON1-BU Santé (693882101) / SudocSudocFranceF

EXPERIENCE DU SUIVI DE PATIENTS AYANT UNE MALADIE D'ALZHEIMER TRAITES PAR DONEPEZIL

LYON1-BU Santé (693882101) / SudocSudocFranceF

Suivi de patients atteints de maladie d'Alzheimer et traités par la galantamine pendant un an

LYON1-BU Santé (693882101) / SudocSudocFranceF

Tolérance et utilisation de l'Exelon® patch chez les patients atteints de la maladie d'Alzheimer (étude prospective)

LYON1-BU Santé (693882101) / SudocSudocFranceF

Study design and protocol of a low to high intensity computer-based cognitive training at home in supplement to standard care in patients with AD

International audienceIntroduction Recent studies on cognitive training in patients with Alzheimer’s disease (AD) showed positive long-term effects on cognition and daily living, suggesting remote computer-based programmes to increase training sessions while reducing patient’s travelling. The aim of this study is to examine short-term and long-term benefits of computer-based cognitive training at home in patients with mild to moderate AD, as a complement to the training in speech and language therapists’ (SLT) offices. The secondary purpose is to study training frequency required to obtain noticeable effects.Methods and analyses This is a national multicentre study, conducted in SLT offices. The patients follow training in one of three conditions: once a week in SLT office only (regular condition) and once a week in SLT office plus one or three times per week at home. The trainings’ content in SLT office and at home is identical. For all three groups near and far transfer will be compared with evaluate training frequency’s effect. Our primary outcome is executive and working memory scores in experimental tasks, and the secondary is neuropsychological tests and questionnaires’ scores. Linear models’ analyses are considered for all measures with a random intercept for patients and another for per practice. The fixed effects will be: three modality groups and time, repeated measures, (T0—pretraining, T1—post-training, T2—long-term follow-up) and the interaction pairs.Ethics and dissemination The study got ethics approval of the national ethical committee CPP Sud Méditerranée III (No 2019-A00458-49) and of the National Commission for Information Technology and Liberties (No 919217). Informed consent is obtained from each participant. Results will be disseminated in oral communications or posters in international conferences and published in scientific journals

Can ICT improve the quality of life of elderly adults living in residential home care units (RHCU)? From actual impacts to hidden artifacts.

37p.International audienceIn a context of progressive loss of intellectual and interactional capacities for the elderly, the goal of this paper is to examine to what extent a new technological environment can improve their quality of life. In this study we examine the very elderly (mean age 87) who have experienced a loss in functional capacities and are dependent on managed care such as residential home care units (RHCU). Using qualitative methods amongst a group of 17 residents (semi-structured interviews and longitudinal observations), we examine whether new social practices form and whether subjects feel more socially recognized. Our study shows that information and communication technologies (ICT) may, to some extent, play an instrumental role in interconnectedness and social stimulation, and can also be seen as a "boundary object" that communicates between the residents' world (who are rather isolated) and their families' world (including grandchildren)